S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:CKPT - Checkpoint Therapeutics Stock Price, Forecast & News

$2.22
+0.02 (+0.91 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$2.16
Now: $2.22
$2.30
50-Day Range
$1.52
MA: $1.83
$2.25
52-Week Range
$1.12
Now: $2.22
$5.20
Volume115,000 shs
Average Volume231,488 shs
Market Capitalization$84.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.68
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.51 million
Book Value$0.42 per share

Profitability

Net Income$-36,370,000.00
Net Margins-583.52%

Miscellaneous

Employees7
Market Cap$84.85 million
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.


Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The company had revenue of $0.28 million for the quarter, compared to analysts' expectations of $0.70 million. Checkpoint Therapeutics had a negative net margin of 583.52% and a negative return on equity of 339.99%. View Checkpoint Therapeutics' Earnings History.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Checkpoint Therapeutics.

What price target have analysts set for CKPT?

2 analysts have issued 12-month price targets for Checkpoint Therapeutics' stock. Their forecasts range from $8.00 to $15.00. On average, they expect Checkpoint Therapeutics' share price to reach $11.50 in the next year. This suggests a possible upside of 418.0% from the stock's current price. View Analyst Price Targets for Checkpoint Therapeutics.

What is the consensus analysts' recommendation for Checkpoint Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Checkpoint Therapeutics.

What are Wall Street analysts saying about Checkpoint Therapeutics stock?

Here are some recent quotes from research analysts about Checkpoint Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, cosibelimab and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2019)
  • 2. According to Zacks Investment Research, "Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. " (3/20/2019)

Has Checkpoint Therapeutics been receiving favorable news coverage?

Media stories about CKPT stock have trended extremely negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Checkpoint Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Checkpoint Therapeutics.

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the folowing people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.28%), Renaissance Technologies LLC (0.31%), Bank of America Corp DE (0.27%), Acadian Asset Management LLC (0.23%), Bank of New York Mellon Corp (0.12%) and UBS Group AG (0.08%). View Institutional Ownership Trends for Checkpoint Therapeutics.

Which institutional investors are selling Checkpoint Therapeutics stock?

CKPT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Checkpoint Therapeutics.

Which institutional investors are buying Checkpoint Therapeutics stock?

CKPT stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Bank of America Corp DE, Acadian Asset Management LLC, Barclays PLC and UBS Group AG. View Insider Buying and Selling for Checkpoint Therapeutics.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $2.22.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $84.85 million and generates $3.51 million in revenue each year. The company earns $-36,370,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.View Additional Information About Checkpoint Therapeutics.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is http://www.checkpointtx.com/.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel